Literature DB >> 18281276

The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation.

Seoung Hoon Lee1, Taesoo Kim, Daewon Jeong, Nacksung Kim, Yongwon Choi.   

Abstract

A spontaneous mutation in Bruton's tyrosine kinase (Btk) induces a defect in B-cell development that results in the immunodeficiency diseases X-linked agammaglobulinemia in humans and X-linked immunodeficiency (Xid) in mice. Here we show an unexpected role of Btk in osteoclast formation. When bone marrow cells derived from Xid mice were stimulated with receptor activator of NF-kappaB ligand, an osteoclast differentiation factor, they did not completely differentiate into mature multinucleated osteoclasts. Moreover, we found that the defects appeared to occur at the stage in which mononuclear preosteoclasts fuse to generate multinucleated cells. Supporting this notion, macrophages from Xid mice also failed to form multinucleated foreign body giant cells. The fusion defect of the Xid mutant osteoclasts was caused by decreased expression of nuclear factor of activated T cells c1 (NFATc1), a master regulator of osteoclast differentiation, as well as reduced expression of various osteoclast fusion-related molecules, such as the d2 isoform of vacuolar H(+)-ATPase V0 domain and the dendritic cell-specific transmembrane protein. This deficiency was completely rescued by the introduction of a constitutively active form of NFATc1 into bone marrow-derived macrophages. Our data provide strong evidence that Btk plays a critical role in osteoclast multinucleation by modulating the activity of NFATc1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18281276      PMCID: PMC2431049          DOI: 10.1074/jbc.M708935200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  BLNK: connecting Syk and Btk to calcium signals.

Authors:  T Kurosaki; S Tsukada
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

Review 2.  Regulation of B-cell signal transduction by adaptor proteins.

Authors:  Tomohiro Kurosaki
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

Review 3.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 4.  Genetic regulation of osteoclast development and function.

Authors:  Steven L Teitelbaum; F Patrick Ross
Journal:  Nat Rev Genet       Date:  2003-08       Impact factor: 53.242

5.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.

Authors:  Hiroshi Takayanagi; Sunhwa Kim; Takako Koga; Hiroshi Nishina; Masashi Isshiki; Hiroki Yoshida; Akio Saiura; Miho Isobe; Taeko Yokochi; Jun-ichiro Inoue; Erwin F Wagner; Tak W Mak; Tatsuhiko Kodama; Tadatsugu Taniguchi
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

6.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene.

Authors:  N Kim; P R Odgren; D K Kim; S C Marks; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 7.  Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins.

Authors:  Lawrence E Samelson
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 8.  Platelet-collagen interaction: is GPVI the central receptor?

Authors:  Bernhard Nieswandt; Steve P Watson
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

9.  NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Kabsun Kim; Seoung-Hoon Lee; Jung Ha Kim; Yongwon Choi; Nacksung Kim
Journal:  Mol Endocrinol       Date:  2007-09-20

10.  Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice.

Authors:  Tomonori Kaifu; Jin Nakahara; Masanori Inui; Kenichi Mishima; Toshihiko Momiyama; Mitsuji Kaji; Akiko Sugahara; Hisami Koito; Azusa Ujike-Asai; Akira Nakamura; Kiyoshi Kanazawa; Kyoko Tan-Takeuchi; Katsunori Iwasaki; Wayne M Yokoyama; Akira Kudo; Michihiro Fujiwara; Hiroaki Asou; Toshiyuki Takai
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

View more
  42 in total

Review 1.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Impairment of osteoblast differentiation due to proliferation-independent telomere dysfunction in mouse models of accelerated aging.

Authors:  Haitao Wang; Qijun Chen; Seoung-Hoon Lee; Yongwon Choi; Frederick Brad Johnson; Robert J Pignolo
Journal:  Aging Cell       Date:  2012-06-11       Impact factor: 9.304

3.  Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro.

Authors:  C Y Luo; L Wang; C Sun; D J Li
Journal:  Cell Mol Immunol       Date:  2010-12-06       Impact factor: 11.530

Review 4.  The roles of Orai and Stim in bone health and disease.

Authors:  Lisa J Robinson; Harry C Blair; John B Barnett; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2019-06-05       Impact factor: 6.817

5.  Bruton tyrosine kinase (Btk) suppresses osteoblastic differentiation.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Kiyoshi Yoshida; Dai Otsuki; Hideki Yoshikawa; Chikahisa Higuchi
Journal:  J Bone Miner Metab       Date:  2014-09-18       Impact factor: 2.626

6.  Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authors:  Yu-Tzu Tai; Betty Y Chang; Sun-Young Kong; Mariateresa Fulciniti; Guang Yang; Yolanda Calle; Yiguo Hu; Jianhong Lin; Jian-Jun Zhao; Antonia Cagnetta; Michele Cea; Michael A Sellitto; Mike Y Zhong; Qiuju Wang; Chirag Acharya; Daniel R Carrasco; Joseph J Buggy; Laurence Elias; Steven P Treon; William Matsui; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2012-06-11       Impact factor: 22.113

7.  Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Authors:  Leila Kokabee; Xianhui Wang; Christopher J Sevinsky; Wei Lin Winnie Wang; Lindsay Cheu; Sridar V Chittur; Morteza Karimipoor; Martin Tenniswood; Douglas S Conklin
Journal:  Cancer Biol Ther       Date:  2015-09-18       Impact factor: 4.742

Review 8.  Cross-regulation of signaling by ITAM-associated receptors.

Authors:  Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

Review 9.  A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways.

Authors:  Lionel B Ivashkiv
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

10.  Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis.

Authors:  Han Kyoung Choi; Hye Ri Kang; Eutteum Jung; Tae Eon Kim; Jing Jing Lin; Soo Young Lee
Journal:  Cell Res       Date:  2013-03-12       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.